Ticker Details
Karyopharm Therapeutics Inc. Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company. It focuses on the discovery, development, and commercialization of first-in-class drugs directed against nuclear transport and related targets to treat cancer and other diseases.
IPO Date:	November 6, 2013
Sector:	Healthcare
Industry:	Drug Manufacturers
Market Cap:	$44.46M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.41 | 3.85%
Avg Daily Range (30 D):	$0.42 | 7.08%
Avg Daily Range (90 D):	$0.36 | 4.77%

Institutional Daily Volume
Avg Daily Volume:	.99M
Avg Daily Volume (30 D):	1.84M
Avg Daily Volume (90 D):	.87M

Trade Size
Avg Trade Size (Sh.):	148
Avg Trade Size (Sh.) (30 D):	158
Avg Trade Size (Sh.) (90 D):	122

Institutional Trades
Total Institutional Trades:	2,387
Avg Institutional Trade:	$1.65M
Avg Institutional Trade (30 D):	$.62M
Avg Institutional Trade (90 D):	$2.12M
Avg Institutional Trade Volume:	.02M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.88M
Avg Closing Trade (30 D):	$.62M
Avg Closing Trade (90 D):	$2.63M
Avg Closing Volume:	18.87K

News

Aug 4, 2026 @ 8:51 PM INVESTOR ALERT: Pomerantz Law Firm Investigates Cl... Source: Pomerantz Llp

Jun 14, 2026 @ 10:30 AM Menarini Group Reports Data from the Phase 3 SENTR... Source: Na

Mar 1, 2025 @ 1:45 PM International Myeloma Foundation (IMF) Celebrates ... Source: International Myeloma Foundation

Nov 25, 2024 @ 4:00 PM Glioblastoma Multiforme Treatment Market Size to R... Source: Precedence Research

Sep 5, 2024 @ 6:16 PM Down -12.14% in 4 Weeks, Here's Why Karyopharm The... Source: Zacks

Financials
	TTM	Q2 2026	Q1 2026
Basic EPS	$-14.16	$-2.32	$-1.02
Diluted EPS	$-14.38	$-2.32	$-1.24
Revenue	$146.62M	$33.43M	$35.07M
Gross Profit
Net Income / Loss	$-224.74M	$-67.02M	$-22.39M
Operating Income / Loss	$-82.35M	$-22.53M	$-26.76M
Cost of Revenue
Net Cash Flow	$16.22M	$-35.87M	$30.28M
PE Ratio

Splits
Feb 26, 2025	1:15